Y-mAbs Therapeutics, Inc.: 5%+ holders

As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Y-mAbs Therapeutics, Inc. The largest reported stake is Anders Hove's, at 6.2%. 9 filings are on record since August 12, 2025 (Schedule 13G/A, August 20, 2025).

Beryl Capital Management LLC also filed stake reports on 4 other companies ↓

Sell to companies like Y-mAbs Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2025-11-14 · Reporting person: Beryl Capital Management LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2025-11-14
• Filing 2025-11-14 · Reporting person: Caligan Partners LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2025-11-14
• Filing 2025-11-14 · Reporting person: HBM Healthcare Investments (Cayman) Ltd. · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2025-11-14
• Filing 2025-11-14 · Reporting person: Paradigm BioCapital Advisors LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2025-11-14
• Filed 2025-11-13 · Holder: Glazer Capital, LLC · Percent: 0% · SCHEDULE 13G/A

Y-mAbs Therapeutics, Inc. has 9 Schedule 13D or 13G filings on record since 2025-08-12. 1 holder's latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Y-mAbs Therapeutics, Inc. and the warning signs.

See Y-mAbs Therapeutics, Inc.'s free Snapshot Watch Y-mAbs Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Y-mAbs Therapeutics, Inc. and the records around it.

Companies that share a holder

• Beryl Capital Management LLC also filed stake reports on 4 other companies: Vigil Neuroscience, Inc. (Nov 2025)
• ACORN BIOVENTURES, L.P. also filed stake reports on 5 other companies: Karyopharm Therapeutics Inc. (Oct 2026), Athira Pharma, Inc. (Aug 2026), enGene Therapeutics Inc. (Jul 2026)
• HBM Healthcare Investments (Cayman) Ltd. also filed stake reports on 7 other companies: Chemomab Therapeutics Ltd. (Sep 2026), ALX ONCOLOGY HOLDINGS INC (May 2026), IO Biotech, Inc. (Apr 2026)

Want the whole picture on Y-mAbs Therapeutics, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Y-mAbs Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Y-mAbs Therapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   9 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing names Y-mAbs Therapeutics, Inc., with its principal executive office as 202 CARNEGIE CENTER, SUITE 301, PRINCETON, NJ 08540 (SCHEDULE 13G/A, 2025-11-14).

Timeline

Swipe the table sideways to see every column.

Questions about who owns Y-mAbs Therapeutics, Inc.

Who owns Y-mAbs Therapeutics, Inc.?

On this page, one holder's latest ownership filing reports 5% or more of Y-mAbs Therapeutics, Inc.: Anders Hove (6.2%, Schedule 13G/A, filed 2025-08-20).

When did Anders Hove buy into Y-mAbs Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Anders Hove on this page is the Schedule 13G/A, filed 2025-08-15, reporting 7%; its latest, Schedule 13G/A filed 2025-08-20, reports 6.2%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Tools for this story

Each opens in a new tab, filled in for Y-mAbs Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Y-mAbs Therapeutics, Inc. is mentioned again
• Find former Y-mAbs Therapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes